Compounding changes in 2026: what changed, what's next, what to ask your provider

Welcome to Issue 01 of Anthivera Insider. We are starting on a regulatory beat because a lot of people we know took a peptide off the shelf in April 2026 and have not yet asked their provider what changed.

Two milestones, both public, both consequential:

1. The FDA narrowed its Category 2 list of bulk drug substances eligible for 503A compounding in April 2026. Approximately a dozen peptides came off.
2. The Pharmacy Compounding Advisory Committee (PCAC) holds its next public review in July 2026.

Here is what we know, what we do not, and what we would bring to a consult right now.

What Category 2 actually means#

Section 503A of the Federal Food, Drug, and Cosmetic Act lets state-licensed compounding pharmacies make custom medications from bulk substances — but only under specific conditions. The FDA maintains a public list of bulk substances explicitly eligible for 503A compounding, a list of substances explicitly ineligible, and a long interim "may compound while we evaluate" middle bucket sometimes called Category 2.

Most peptides have historically lived in that middle bucket. The April 2026 movement narrowed it.

In plain language: a peptide that was previously in pharmacy-formulary limbo is now either explicitly compoundable (rare, post-evaluation), or has been removed from the interim list — which means most 503A pharmacies will no longer fill orders for it.

What changed in practice#

Without naming specific peptides until the FDA's revised lists are fully indexed and the agency's interim guidance has been published in full, the broad pattern is this:

• Peptides with thin human-trial data and significant adverse-event reporting moved off the eligible list.
• Peptides with stronger trial backing moved closer to outright approval pathways and remain available.
• Several compounds that were widely available through 2025 are now in limbo pending the July 2026 review.

What it means for telehealth peptide providers#

Most telehealth peptide providers contract with a specific 503A or 503B partner pharmacy. When the eligible-substance list contracts, three things happen in sequence:

1. The pharmacy stops accepting new orders for affected peptides.
2. The provider's protocol library narrows.
3. Patients on existing protocols receive notice of substitution, discontinuation, or transition to an alternative.

If you are currently on a peptide protocol via a telehealth provider, the relevant question is not "is my peptide still legal." It is "is my pharmacy still filling it for me?"

What we would ask a provider right now#

• Which 503A or 503B pharmacy do you use, and are they affected by the April 2026 list revisions?
• For any peptide I am currently on or considering: is it on the eligible list, on the ineligible list, or pending PCAC review in July 2026?
• If a substitution is recommended, what is the evidence base for the substitute, and how does it compare to what I was using?
• What is your plan if July's PCAC review changes status again?

What is next#

The July 2026 PCAC meeting is the next milestone. Compounding-committee decisions are not the same as drug approvals — but they shape what is available, what is evidence-validated, and what the FDA will tolerate in the interim. We will cover the meeting outcomes in a future issue.

For the underlying regulatory text, the FDA maintains its 503A bulk-substances guidance at fda.gov. Always verify current list status with a licensed pharmacist or your provider before making medication decisions.

— The Anthivera editors